Blanchard-Rohner G, Caprettini B, Rohner D, et al.. effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination Ipragliflozin L-Proline among children. Keywords: vaccine acceptance, SARS-CoV-2, COVID-19 vaccine, MIS-C, PIMS Vaccination against SARS-CoV-2 has demonstrated remarkable efficacy in averting multisystem inflammatory syndrome (MIS-C) following SARS-CoV-2 contamination in adolescents and children.1,2 In Switzerland, SARS-CoV-2 vaccination was recommended for children 16 years of age and above starting from May 2021 onward, followed by an extension to children 12 years old and above from June 2021. Subsequently, from December 2021, children 5 years of age and above were included in the vaccination recommendation.3 Several countries, including the United States,4 Canada5 and Switzerland, recommended SARS-CoV-2 vaccination for children who had experienced MIS-C. The rationale behind this recommendation rested around the potential to prevent recurrence of MIS-C through vaccination, considering that COVID-19 vaccination did not exhibit evidence of being a risk factor for MIS-C, while SARS-CoV-2 contamination was unequivocally recognized as a risk factor for MIS-C. In addition, the vaccine was well tolerated in MIS-C children and was not associated to any relapse of MIS-C episode.6,7 In other countries, the vaccination strategy for children post-MIS-C was debated. In France, for instance, SARS-CoV-2 vaccination was initially contraindicated in this populace but their position was revised in February 2022 to recommend vaccination.8 Limited research has been conducted on parental vaccination and attitudes toward vaccination of children who have experienced MIS-C. METHODS This is an ancillary study nested in the prospective Swissped RECOVERY trial of the Swiss National Clinical Trials Portal (SNCTP000004720) and clinicaltrial.gov (NCT Ipragliflozin L-Proline 04826588), an investigator-initiated randomized multicenter open-label 2-arm trial in which children hospitalized with MIS-C were randomly assigned 1:1 to intravenous immunoglobulins or intravenous methylprednisolone at 10 Swiss pediatric hospitals.9,10 Cohort characteristics and outcomes have been published previously.9 Included children were Rabbit polyclonal to VCL followed until 6 months after randomization, and their families received a questionnaire (Questionnaire, Supplemental Digital Content 2, http://links.lww.com/INF/F338) regarding COVID-19 vaccination at 6 months after hospital discharge. For parents, the criterion for not being opposed to vaccination was having received at least 1 dose of the SARS-CoV-2 vaccine. This approach was adopted due to the absence of information regarding parental demographics, underlying health conditions, occupation or historical exposure, factors that would have enabled us to determine the requisite quantity of vaccine doses for considering vaccination as total. Data were summarized using the number Ipragliflozin L-Proline (percentage) for categorical variables and the median (interquartile range) for continuous variables. Summary statistic comparisons between groups were performed using the Fisher exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. All analyses were based on the complete case data only and were performed using the statistical software R (version 4.0.3, R Development Core Team, Vienna, Austria11). A significance level of 5% was utilized for all statistical analysis. RESULTS Between May 21, 2021 and April 15, 2022, a total of 75 patients were included in the intention-to-treat analysis. Detailed information around the cohort, including baseline characteristics, is offered in the original publication.9 The vaccination questionnaire was completed for 56 children presenting with a MIS-C (74%; 56/75), resulting in 56 patients and 112 parents with available data for this analysis. We have included the patient characteristics from the original manuscript in Table, Supplemental Digital Content 3, http://links.lww.com/INF/F339 (Total patients) to observe any important difference that could suggest a bias in our analysis. No big differences between the 2 populations were observed. Before the occurrence of MIS-C in their offspring, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 and 70% (78/112) after the MIS-C episode. Among the 73 parents who experienced previously been vaccinated, 21% (15/73) received additional doses of the vaccine after the MIS-C episode of their child. In the group of parents who experienced in the beginning chosen not to get vaccinated, 11% (4/37) got vaccinated (1 parent received a single dose, 2 received 2 doses and 1 received 3.